%0 Journal Article
%T 介绍一种不影响D<sub>2</sub>受体的新型抗精神病候选药物&#65306;SEP-363856<br>Introducing a Novel Antipsychotic Candidate Drug That Does Not Affect D<sub>2</sub> Receptors: SEP-363856
%A 周小东
%A 刘知霞
%A 贾慧贤
%A 胡兴娟
%A 王朋
%A 张俊纳
%A 刘知源
%A 张光勇
%J Pharmacy Information
%P 475-481
%@ 2160-4452
%D 2024
%I Hans Publishing
%R 10.12677/pi.2024.136056
%X 本文介绍一种在2020年被美国FDA批准用于临床精神分裂症的新型抗精神分裂症药物&#65306;SEP-363856。从该药物的药代动力学、受体作用机制、临床运用情况以及安全性和不良反应等方面作了总结。结论&#65306;SEP-363856治疗精神分裂症的阴、阳性症状均有效&#65292;且安全性、耐受性好&#65292;需要进一步扩大样本研究。<br>The article introduces a novel antipsychotic drug, SEP-363856, approved by US FDA for clinical use in schizophrenia in 2020. A summary was made on the pharmacokinetics, receptor mechanism of action, clinical application, safety, and adverse reactions of the drug. Conclusion: SEP-363856 is effective in treating both negative and positive symptoms of schizophrenia and is safe and well tolerated. Further expansion of sample research is needed.
%K 新型抗精神病药物(SEP-363856)&#65292
%K 精神分裂症&#65292
%K 疗效&#65292
%K 安全性&#65292
%K 耐受性<br>Novel Psychotropic Agent (SEP-363856)
%K Schizophrenia
%K Effect
%K Safety
%K Tolerance
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=101211